Shots:
In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value
This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
Shots:
The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental care
The global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030
PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…
Shots:
A longstanding equities business within Citadel, Surveyor Capital invests in the consumer, financials, healthcare, industrials, and Technology, Media & Telecom sectors
In 2023, Surveyor participated in four funding rounds, investing approximately $2.35B and adding 17 companies to its portfolio
For a curated report on a specific investor or venture capital firm, reach out to…
Shots:
Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseases
In 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…
Shots:
CDMOs are at the forefront of pharmaceutical manufacturing, shaping the industry's growth by meeting the increasing global demand for pharmaceutical products
In 2023, the global CDMO market was valued at $224.86B, with projections to reach $465.14B by 2032, demonstrating a CAGR of 8.5%
PharmaShots presents a comprehensive report on the 20 Contract Development and…
Shots:
A New York-based venture capital fund, Catalio Capital Management invests in breakthrough MedTech and innovative healthcare companies globally
In 2023, Catalio Capital participated in eight funding rounds and invested approximately $1.82B to add 22 companies to its portfolio
For a curated report on a specific investor or venture capital firm, reach out to us…
Shots:
Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases
In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…
Shots:
A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines
In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …

